Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Letter

Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives

D Gareth R Evans12*, Anthony Howell1, Sarah L Ingham13 and Iain Buchan3

Author Affiliations

1 Genesis Breast Cancer Prevention Centre, University Hospital of South Manchester NHS Trust, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK

2 Genetic Medicine, The University of Manchester, Manchester Academic Health Science Centre, Central Manchester Foundation Trust, St. Mary's Hospital, Oxford Road, Manchester, M13 9WL, UK

3 NIBHI, Centre for Health Informatics, Institute of Population Health, Jean McFarlane Building, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK

For all author emails, please log on.

Breast Cancer Research 2013, 15:401  doi:10.1186/bcr3382


See related research by Rhiem et al., http://breast-cancer-research.com/content/14/6/R156

Published: 26 February 2013

First paragraph (this article has no abstract)

In the previous issue of Breast Cancer Research, Rhiem and colleagues [1] report contralateral breast cancer risks in relatives of BRCA1/2 mutation carriers as well as those testing negative. The authors quote 25-year risks of 44.1% for BRCA1 and 33.5% for BRCA2. The risks quoted are somewhat lower than might be inferred from previous estimates in BRCA1/2 carriers, which have been as high as 40% at 10 years [2]. This discrepancy may be explained in part by the decision to exclude index cases in which there may have been testing bias to bilateral disease. However, the authors dismiss a second bias of including many non-carriers in their analysis as 'putative' carriers.